Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. If you experience chest pain, shortness of breath, or signs of a heart attack or stroke, call 911 immediately.

Diabetes and Heart Disease: Reducing Your Risk

Creator: Editorial Team
Published: 2026-03-28

Last updated: March 2026 | Reviewed by MDTalks Editorial Team

Heart disease is the leading cause of death among people with diabetes. Adults with diabetes have approximately twice the risk of coronary heart disease and two to four times the risk of stroke compared to adults without diabetes. Cardiovascular disease accounts for more diabetes-related deaths than any other complication. Yet significant advances in treatment, including newer medication classes and more aggressive risk factor management, have made cardiovascular risk reduction a central pillar of modern diabetes care.

Why Diabetes Increases Heart Risk

Diabetes accelerates atherosclerosis (the buildup of fatty plaques in arteries) through multiple pathways:

Chronic hyperglycemia damages the endothelium (inner lining of blood vessels), promoting plaque formation
Insulin resistance is associated with inflammation, abnormal lipid profiles, and elevated blood pressure
Dyslipidemia common in type 2 diabetes (high triglycerides, low HDL, small dense LDL particles) is particularly atherogenic
Hypertension affects approximately 70% of adults with type 2 diabetes
Obesity contributes to both diabetes and cardiovascular disease through shared inflammatory and metabolic pathways
Hypercoagulability (increased tendency to form blood clots) is more prevalent in diabetes

These risk factors cluster together. Most people with type 2 diabetes have two or more cardiovascular risk factors in addition to elevated blood sugar.

Cardiovascular Risk Assessment

The 2026 ADA Standards of Care recommend systematic cardiovascular risk factor assessment at least annually for all people with diabetes, including:

Risk Factor	How It’s Measured	Target
Blood pressure	Office measurement	Below 120/80 mmHg (high-risk patients per 2026 ADA)
LDL cholesterol	Fasting lipid panel	Below 70 mg/dL (with ASCVD) or below 100 mg/dL (primary prevention)
Triglycerides	Fasting lipid panel	Below 150 mg/dL
A1C	Blood test	Below 7% (individualized)
Smoking status	Patient history	Cessation
BMI/Weight	Height and weight	BMI below 25 (or 5%+ weight loss if overweight)
Kidney function	eGFR + uACR	Monitor annually; treat albuminuria

The BPROAD trial, referenced in the 2026 ADA Standards, demonstrated that intensive blood pressure treatment (achieving mean 121.6 mmHg vs. 133.2 mmHg) reduced major cardiovascular events by 21% in people with diabetes.

Risk Reduction Strategies

Medications with Cardiovascular Benefit

Two diabetes medication classes have demonstrated independent cardiovascular protection:

GLP-1 receptor agonists reduce major adverse cardiovascular events, heart failure hospitalization, kidney events, and all-cause mortality. The LEADER (liraglutide), SUSTAIN-6 (semaglutide), and REWIND (dulaglutide) trials established these benefits. See GLP-1 Medications: Ozempic, Mounjaro, and Beyond.

SGLT2 inhibitors reduce cardiovascular death, heart failure hospitalization, and kidney disease progression. The EMPA-REG OUTCOME, DECLARE-TIMI 58, and CANVAS trials demonstrated these benefits. Both empagliflozin and dapagliflozin are now approved for heart failure regardless of diabetes status. See SGLT2 Inhibitors: How They Work for Diabetes.

The 2026 ADA Standards consider these agents fundamental elements of cardiovascular risk reduction and recommend them for patients with type 2 diabetes and established cardiovascular disease, heart failure, or high cardiovascular risk, regardless of A1C.

Statin Therapy

Statin medications are recommended for nearly all adults with diabetes:

Age 40–75 without ASCVD: Moderate-intensity statin (atorvastatin 10–20 mg or rosuvastatin 5–10 mg)
With ASCVD or high risk: High-intensity statin (atorvastatin 40–80 mg or rosuvastatin 20–40 mg)
LDL target with ASCVD: Below 70 mg/dL; some guidelines recommend below 55 mg/dL for very high risk

Blood Pressure Management

ACE inhibitors or ARBs are first-line for hypertension in diabetes, especially with albuminuria. The more aggressive target of below 120 mmHg systolic, supported by the BPROAD trial, represents a shift from the previous 130 mmHg recommendation for high-risk patients.

Aspirin

Low-dose aspirin (75–162 mg/day) may be considered for secondary prevention in people with diabetes and established cardiovascular disease. For primary prevention, the risks and benefits should be discussed individually with your provider.

Lifestyle Modifications

Exercise: At least 150 minutes per week of moderate aerobic activity. See Exercise and Diabetes: Safe Workout Guidelines.
Diet: Mediterranean or DASH dietary patterns have the strongest evidence for cardiovascular protection. See Diabetic Diet: Low-Carb, Mediterranean, and Plant-Based.
Smoking cessation: Smoking doubles cardiovascular risk in diabetes. Quitting is the single most impactful lifestyle change.
Weight management: Even 5%–10% weight loss reduces cardiovascular risk factors.

Warning Signs of Heart Disease

Seek immediate medical attention (call 911) for:

Chest pain or pressure (especially with exertion or stress)
Shortness of breath
Pain radiating to the arm, jaw, neck, or back
Sudden dizziness or lightheadedness
Nausea or cold sweat

People with diabetes (especially those with autonomic neuropathy) may have atypical presentations, including painless (“silent”) heart attacks. Regular cardiac screening and awareness of atypical symptoms are important.

For the complete diabetes management approach, see the Complete Guide to Diabetes Management in 2026.

Key Takeaways

Heart disease is the leading cause of death in people with diabetes; adults with diabetes have approximately twice the cardiovascular risk.
The 2026 ADA Standards recommend annual cardiovascular risk assessment, a blood pressure target below 120 mmHg for high-risk patients, and statin therapy for most adults with diabetes.
GLP-1 receptor agonists and SGLT2 inhibitors provide cardiovascular protection beyond glucose lowering and are recommended for high-risk patients regardless of A1C.
Lifestyle modifications (exercise, Mediterranean diet, smoking cessation, weight management) are foundational and additive to pharmacological interventions.
People with diabetes may have atypical heart attack symptoms; know the warning signs and seek emergency care immediately.
Consult your healthcare provider for a comprehensive cardiovascular risk assessment and personalized treatment plan.

Sources

American Diabetes Association. “10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes — 2026.” Diabetes Care, January 2026. pmc.ncbi.nlm.nih.gov
Centers for Disease Control and Prevention. “Diabetes and Heart Disease.” cdc.gov/diabetes
National Center for Biotechnology Information. “Heart Disease and Diabetes.” Diabetes in America, 2023. ncbi.nlm.nih.gov

This article is part of the MDTalks Diabetes Hub. See also AI Answers About High Blood Pressure and AI Answers About Cholesterol.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. If you experience chest pain or signs of a heart attack, call 911 immediately.